Enterprise Value
419.7M
Cash
795.7M
Avg Qtr Burn
-30.01M
Short % of Float
13.54%
Insider Ownership
28.34%
Institutional Own.
46.99%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bebtelovimab (LY-CoV1404) Details COVID-19 | Approved Update | |
Bamlanivimab (LY-CoV555) Details COVID-19 | Approved Quarterly sales |